Detalles de la búsqueda
1.
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
J Dtsch Dermatol Ges
; 22(1): 34-42, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926830
2.
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
J Eur Acad Dermatol Venereol
; 37(1): 93-103, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36156312
3.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Eur Acad Dermatol Venereol
; 37(5): 1017-1027, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695061
4.
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Dermatol Ther
; 35(12): e15866, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36175129
5.
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Dermatol Ther
; 35(10): e15670, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762118
6.
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
Dermatol Ther
; 35(12): e15917, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36214268
7.
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
Dermatol Ther
; 35(11): e15803, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062429
8.
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Dermatol Ther
; 35(5): e15378, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156278
9.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Dermatol Ther
; 35(8): e15608, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638250
10.
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Dermatol Ther
; 35(1): e15166, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676662
11.
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.
Acta Derm Venereol
; 102: adv00821, 2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36065745
12.
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
J Allergy Clin Immunol
; 147(2): 558-560.e1, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33160968
13.
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
Acta Derm Venereol
; 101(11): adv00605, 2021 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34596230
14.
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Acta Derm Venereol
; 101(10): adv00576, 2021 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33903916
15.
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
BMC Health Serv Res
; 21(1): 924, 2021 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34488749
16.
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
Exp Dermatol
; 32(9): 1591-1594, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395012
17.
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
Exp Dermatol
; 32(12): 2187-2188, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541075
18.
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.
Acta Derm Venereol
; 103: adv5278, 2023 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37073963
19.
Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study.
Acta Derm Venereol
; 103: adv4526, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36987538
20.
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
Clin Exp Dermatol
; 48(4): 379-381, 2023 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36745578